Why in news?
The Central Drugs Standard Control Organisation (CDSCO) has announced that it will fast‑track approvals for new medicines by issuing No‑Objection Certificates (NOCs) for laboratory testing immediately upon receiving applications. The new procedure aims to reduce delays in bringing new drugs to market.
Background
CDSCO is India’s national regulatory authority for drugs and medical devices. Operating under the Ministry of Health and Family Welfare, it oversees the import, manufacture, sale and distribution of medicines. Headed by the Drugs Controller General of India (DCGI), the agency approves new drugs and clinical trials, sets quality standards, and coordinates with State regulators. Special categories such as blood products, vaccines and sera are licensed jointly by CDSCO and state authorities.
What is changing?
- Immediate NOCs: Under the revised procedure, applications seeking permission to import or manufacture new drugs will receive an NOC for laboratory testing upfront instead of waiting for technical scrutiny.
- Parallel review: Detailed regulatory review of formulation, dosage and compliance with pharmacopoeial standards will continue while testing proceeds.
- Testing facilities: Designated government laboratories – including the Indian Pharmacopoeia Commission in Ghaziabad, Central Drugs Testing Laboratory in Mumbai, Central Drugs Laboratory at CRI Kasauli and the National Institute of Biologicals in Noida – will conduct the tests.
- Effective date: The new system will take effect on 1 June 2026. Applicants must still provide finalised specifications based on quality management systems. If specifications change after review, a fresh NOC will be required.
Significance
By allowing testing to begin immediately, CDSCO hopes to speed up the availability of new drugs without compromising safety. The parallel review process maintains quality oversight while reducing procedural bottlenecks. Faster approvals will benefit patients and pharmaceutical companies alike, especially for critical medicines.
Source: The Times of India